BLADDER: METASTATIC: 2nd LINE: TROPION-Urothelial03

Study snapshot

Unresectable locally advanced or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra
No urachal, small cell, or adenocarcinoma are allowed
Squamous differentiation or mixed cell types are eligible if histology is predominantly transitional cell
Must have had progression of disease after the combination of enfortamab vedotin and pembrolizumab. Can have stopped EV+pembro due to toxicity as long as has had disease progression since then.
No metastatic prostate cancer, but early stage prostate cancer is allowed if there is no rising PSA and is not currently getting ADT
Must have tumor tissue sample (can be archival)
Must be eligible to receive platinum containing chemotherapy
If patient received gemcitabine, carboplatin, or cisplatin for early UC, at least 1 year must have passed since the last dose
No prior TROP2 directed ADC therapy
No uncontrolled or significant cardiac disease
No history of pneumonitis or clinically severe pulmonary disease